[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][Branch1][C][C][C][C][C][C][C][C][C][C][C][=Branch1][C][=O][N][C@@H1][C@H1][Branch2][#C][O][C@@H1][Branch2][#C][=Branch1][C@H1][Branch2][=C][=N][O][C@H1][Ring1][=Branch1][O][C][=C][C][=C][C][=C][Ring1][=Branch1][O][C][=C][Branch2][=N][=Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C@H1][Branch2][N][N][C@H1][C][=Branch1][C][=O][N][C][Branch2][O][Branch1][C][=C][Branch2][Ring2][C][C][=Branch1][=Branch2][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][O][O][C@@H1][C@H1][Branch1][P][C@H1][Branch1][=N][C@@H1][Branch1][=Branch2][C@H1][Branch1][Ring2][O][Ring1][=Branch1][C][O][O][O][O][C][=C][Branch2][Branch2][=Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C@H1][Branch1][=Branch2][C][=Branch1][C][=O][N][Ring2][Ring2][C][N][C][=Branch1][C][=O][C@@H1][Ring2][Ring2][P][N][C][=Branch1][C][=O][C@@H1][C][=C][Branch2][Branch1][P][C][=Branch2][Branch1][N][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][O][C][=C][Branch2][Ring2][=C][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C@H1][Branch2][Ring1][S][C][=Branch1][C][=O][N][C@H1][Branch1][S][C][C][=C][C][=C][Branch1][Branch1][O][Ring2][=Branch1][#C][C][=C][Ring1][#Branch1][C][=Branch1][C][=O][N][Ring2][Ring1][=C][N][C][O][O][Cl][O][C][=Branch1][C][=O][N][C][C][C][N][Branch1][C][C][C][O][Cl][C][=Branch1][C][=O][O][O][O]"}, {"from": "gpt", "value": "The molecule is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains). Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking."}]